Jon Thor Asmussen

TL;DR: The Myeloma Response Assessment and Diagnosis System (or MY-RADS) imaging recommendations are designed to promote standardization and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI in myeloma and allow response assessment.

TL;DR: None of the modalities can yet replace surgical staging, however, they all contributed to important knowledge and were able to upstage low-risk patients who would not have been recommended lymph node resection based on histology and grade alone.

TL;DR: A clinical imaging strategy based on PET/CT demonstrated a significantly higher detection rate of distant metastasis or synchronous cancer than strategies in current clinical imaging guidelines, of which European ones primarily recommend CXR/MRI, whereas U.S. guidelines preferably point to CHCT/MRI in patients with head and neck squamous cell carcinoma.

TL;DR: The sensitivity and specificity of the SUVmax in staging endometrial cancer is not high enough to reliably replace surgical staging, and preoperative PET/CT scanning and SUVmax measurements of the primary tumour may provide additional clinical and prognostic information about myometrial invasion, CI, LNM and high risk disease.

TL;DR: For diagnosing MBD, low-dose whole-body CT is now recommended over conventional skeletal survey, but also more advanced functional imaging modalities, such as diffusion-weighted MRI and PET/CT are increasingly important in the assessment and monitoring of MBD.